cpi-006
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Apr 25, 2018 (NCT03454451)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- COVID-19 · Phase 3
- Endometrial Neoplasms · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- 5'-nucleotidaseINHIBITOR
NT5E inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04734873 | Phase 3 | Feb 25, 2021 | Corvus Pharmaceuticals, Inc. |
| NCT04464395 | Phase 1 | Jul 1, 2020 | Corvus Pharmaceuticals, Inc. |
| NCT03454451 | Phase 1 | Apr 25, 2018 | Corvus Pharmaceuticals, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | For profit | 3 | 3 | 2 | 2018 |
1 organizations
Page 1 / 1